UY36801A - PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM - Google Patents

PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM

Info

Publication number
UY36801A
UY36801A UY0001036801A UY36801A UY36801A UY 36801 A UY36801 A UY 36801A UY 0001036801 A UY0001036801 A UY 0001036801A UY 36801 A UY36801 A UY 36801A UY 36801 A UY36801 A UY 36801A
Authority
UY
Uruguay
Prior art keywords
infections
prevention
treatment
procedure
composition
Prior art date
Application number
UY0001036801A
Other languages
English (en)
Inventor
Barnett Thomas
David A Ross
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of UY36801A publication Critical patent/UY36801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Realizaciones de la presente invención dan a conocer métodos para el tratamiento o la prevención de afecciones inmunitarias relacionadas con infecciones utilizando composiciones que comprenden IgM.
UY0001036801A 2015-08-06 2016-07-19 PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM UY36801A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201917P 2015-08-06 2015-08-06

Publications (1)

Publication Number Publication Date
UY36801A true UY36801A (es) 2016-09-30

Family

ID=56464076

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036801A UY36801A (es) 2015-08-06 2016-07-19 PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM

Country Status (16)

Country Link
US (5) US9913903B2 (es)
EP (2) EP3150629A3 (es)
JP (1) JP6901245B2 (es)
KR (1) KR20170017832A (es)
CN (1) CN106421780A (es)
AR (1) AR105596A1 (es)
AU (1) AU2016208291B2 (es)
BR (1) BR102016017840A2 (es)
CA (1) CA2936745A1 (es)
CL (1) CL2016001977A1 (es)
IL (1) IL246918B (es)
MX (1) MX2016009888A (es)
RU (1) RU2733377C2 (es)
SG (2) SG10201606200RA (es)
TW (1) TWI722003B (es)
UY (1) UY36801A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2 (en) * 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
MX2021006212A (es) * 2018-11-30 2021-08-11 Csl Behring Ag Metodos y composiciones para prevenir o tratar exacerbaciones agudas con inmunoglobulina policlonal.
CN114747535B (zh) * 2022-03-29 2024-03-22 华南理工大学 一种急性脓毒症非人灵长类动物模型及其构建方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
GB8426464D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4918163A (en) 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
EP1168912B1 (en) * 1999-03-23 2007-05-09 Hibernation Therapeutics Limited Organ arrest, protection and preservation
RU2191031C2 (ru) * 2001-01-10 2002-10-20 Московский НИИ педиатрии и детской хирургии Способ лечения пневмоний у глубоконедоношенных детей, находящихся на искусственной вентиляции легких
CA2551760A1 (en) * 2003-01-02 2004-07-22 Pedersen Medical A/S Antimicrobial composition for local use on mucosal membranes and skin
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
US7794721B2 (en) * 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
EP2291196A4 (en) 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM

Also Published As

Publication number Publication date
JP6901245B2 (ja) 2021-07-14
EP4036110A1 (en) 2022-08-03
MX2016009888A (es) 2017-02-06
KR20170017832A (ko) 2017-02-15
AU2016208291A1 (en) 2017-02-23
SG10202001028QA (en) 2020-04-29
RU2016131197A3 (es) 2019-12-17
RU2016131197A (ru) 2018-02-01
JP2017036263A (ja) 2017-02-16
AR105596A1 (es) 2017-10-18
IL246918B (en) 2021-02-28
US20230077855A1 (en) 2023-03-16
US9913903B2 (en) 2018-03-13
IL246918A0 (en) 2016-12-29
AU2016208291B2 (en) 2022-04-28
US20200237912A1 (en) 2020-07-30
SG10201606200RA (en) 2017-03-30
CN106421780A (zh) 2017-02-22
BR102016017840A2 (pt) 2017-02-07
US20190358325A1 (en) 2019-11-28
US20170035882A1 (en) 2017-02-09
EP3150629A3 (en) 2017-04-19
EP3150629A2 (en) 2017-04-05
TW201705984A (zh) 2017-02-16
US20180153991A1 (en) 2018-06-07
RU2733377C2 (ru) 2020-10-01
US10660956B2 (en) 2020-05-26
CA2936745A1 (en) 2017-02-06
CL2016001977A1 (es) 2017-03-17
TWI722003B (zh) 2021-03-21

Similar Documents

Publication Publication Date Title
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CL2017001046A1 (es) Inhibidoes del bromodominio
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
BR112017009623A2 (pt) composição de limpeza
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
BR112017009277A2 (pt) compostos de silicone
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CL2017000152A1 (es) Derivados de isoindolinona
CR20170005A (es) Derivados de insoindolina
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
ECSP17074919A (es) Piroglutamato de vortioxetina
UY36801A (es) PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM
CL2017000151A1 (es) Derivados de piridona
ES2982489T3 (es) Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230821